Scancell to begin SCIB1 UK trial as FDA issues linger in US
19th Aug 2019 09:33
(Sharecast News) - Immunotherapy developer Scancell announced the initiation of and further updates to the 'SCIB1' phase 2 trial in patients with metastatic melanoma also receiving the checkpoint inhibitor 'pembrolizumab' (Keytruda) on Monday.
Read moreScancell partnership with Cancer Research moves closer to clinic
20th May 2019 11:03
(Sharecast News) - Immunotherapy developer Scancell Holdings updated the market on its clinical development partnership with Cancer Research UK for the development of the ;ImmunoBody' vaccine, SCIB2, as a potential treatment for patients with solid tumours, including non-small cell lung cancer (NSCLC), on Monday.
Read moreScancell gets go-ahead for UK second phase trials of 'SCIB1'
25th Apr 2019 11:19
(Sharecast News) - Cancer immunotherapy developer Scancell Holdings has received all of the UK regulatory, ethical and legal approvals required to initiate the phase 2 clinical trial to assess the safety and efficacy of 'SCIB1' in metastatic melanoma patients also receiving the checkpoint inhibitor pembrolizumab (Keytruda), it announced on Thursday.
Read moreScancell Holdings expands IP protection with Japanese patent
8th Apr 2019 11:34
(Sharecast News) - Scancell Holdings on Monday won a Japanese patent for its Moditope immunotherapy platform, which stimulates the production of cells that overcome the immune suppression induced by tumours.
Read moreScancell shares slip as losses widen in first half
31st Jan 2019 09:48
(Sharecast News) - Cancer immunotherapies developer Scancell Holdings issued its interim results for the six months ended 31 October on Thursday, reporting a loss of £3.24m, widening from £2.02m year-on-year.
Read moreScancell loses out on Cancer Research UK grant
23rd Jan 2019 11:20
(Sharecast News) - Immunotherapies developer Scancell has seen Cancer Research UK pass on its submission into the Grand Challenge research initiative.
Read moreScancell appoints new heads of research and manufacturing
21st Jan 2019 12:30
(Sharecast News) - Immunotherapy developer Scancell Holdings announced the appointment of Dr Samantha Paston as its head of research, and Dr Adrian Parry as its head of manufacturing, on Monday.
Read moreScancell pleased with progress on 'Moditope' vaccines
30th Oct 2018 14:36
(Sharecast News) - Novel immunotherapies developer Scancell Holdings updated the market on the development of its second vaccine from its proprietary 'Moditope' platform, Modi-2, on Tuesday, reporting that pre-clinical data demonstrated that homocitrullinated peptides induced highly potent T-cell responses, tumour rejection and increased survival in murine models.
Read moreScancell to develop ImmunoBody lung cancer treatment
10th Oct 2016 11:42
(ShareCast News) - Cancer immunotherapy development company Scancell Holdings announced on Monday its intention to develop its SCIB2 ImmunoBody for the treatment of non-small cell lung cancer in combination with a checkpoint inhibitor. The AIM-traded firm's board approved the decision based on the o
Read moreScancell Holdings widens full year loss on US investment
16th Sep 2016 14:24
(ShareCast News) - Scancell Holdings, a developer of novel immunotherapies for the treatment of cancer, has reported a third consecutive full year loss due to the costs involved in its expansion in the US. The firm has seen a 3% increase in its operating loss over the last three years. The loss was
Read moreScancell granted product licence extension from Ichor Medical Systems
20th Jul 2016 12:35
(ShareCast News) - Scancell, the developer of immunotherapies for cancer treatments, was granted a product licence option extension from Ichor Medical Systems. The extension is to licence the commercial use of Ichor's TriGrid electroporation delivery system with SCIB1, Scancell's ImmunoBody vaccine,
Read moreScancell suspends dosing with current supplies of SCIB1 for melanoma
17th Jun 2016 12:24
(ShareCast News) - Shares in drug developer Scancell Holdings plunged almost 17% after it suspending dosing with current clinical trial supplies of SCIB1 for melanoma with immediate effect. Patients would be notified as soon as possible. AIM-quoted Scancell said quality-control analysis showed the
Read moreScancell raises £6.2m in placing and open offer
4th Apr 2016 11:47
(ShareCast News) - Scancell revealed the final results of its placing and open offer on Monday, with a few more subscriptions received since the firm's last update on 1 April. The AIM-traded company had announced on Friday that it had received subscriptions for 16,048,593 new ordinary shares of the
Read moreScancell skips higher on Swedish research collaboration
11th Mar 2016 08:51
(ShareCast News) - Immuno-oncology specialist Scancell has impressed investors with a new research partnership with Sweden's Karolinska Institutet into the role of citrullinated proteins in the treatment of cancer. Both parties have uncovered important roles that citrullinated proteins can play in h
Read moreBigger loss but positive drug trial results for Scancell Holdings
18th Sep 2015 09:23
(ShareCast News) - Scancell Holdings's losses increased marginally in the year ended 30 April 2015. The cancer immunotherapy developer announced on Friday a wider loss of £2.414m from £2.222m last year. It comes as a result of expected additional expenditure on its SCIB1 ImmunoBody clinical trials
Read more